Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer.
about
Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer.Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus.A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis.Intensity modulated radiation therapy with simultaneous integrated boost based dose escalation on neoadjuvant chemoradiation therapy for locally advanced distal esophageal adenocarcinoma.Comparison of cisplatinum/paclitaxel with cisplatinum/5-fluorouracil as first-line therapy for nonsurgical locally advanced esophageal squamous cell carcinoma patients.Present status and progress of neoadjuvant chemoradiotherapy for esophageal cancer.Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study.Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.Influence of tumor response and treatment schedule on the distribution of tumor recurrence in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.
P2860
Q35375231-D14E1350-7524-4050-BEA9-6AD26A73A3D2Q36222524-351DA7E0-A5EF-4E80-BEB0-412AB2620EFDQ36359020-4E7C6D2B-D018-4F00-BC1D-25FFB221EA1CQ36897515-7D182799-D373-47FB-AE08-32B57EE5C8D1Q37074909-F0E1A250-036A-4883-AD11-B094BF079AAEQ38107463-059A0564-8467-4772-9C80-18FAFFF80574Q41622068-96D19E48-912E-4E2A-A54B-6B136D40F857Q43550190-86EEA3F8-B887-42D9-A629-228F005A9935Q45714550-7AA08581-7C9E-4A47-B027-E3A4C7BCC8E0Q48157174-BEFE30F6-0446-4ECE-B649-73FEC38C83E2Q52875208-29D863BE-6B60-466F-BA23-E6759FB0A082Q53122371-704AACCF-06CE-462C-8356-944B516DDB1C
P2860
Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Quantifying the benefit of a p ...... reatment of esophageal cancer.
@en
Quantifying the benefit of a p ...... reatment of esophageal cancer.
@nl
type
label
Quantifying the benefit of a p ...... reatment of esophageal cancer.
@en
Quantifying the benefit of a p ...... reatment of esophageal cancer.
@nl
prefLabel
Quantifying the benefit of a p ...... reatment of esophageal cancer.
@en
Quantifying the benefit of a p ...... reatment of esophageal cancer.
@nl
P2093
P1476
Quantifying the benefit of a p ...... reatment of esophageal cancer.
@en
P2093
Achilles J Fakiris
Peter A S Johnstone
Richard V Scheer
P304
P356
10.1016/J.IJROBP.2010.03.003
P407
P577
2010-06-30T00:00:00Z